Methylprednisolone
Sodium Succinate (Solu-Medrol)
Category:
Description:
Indications:
-
Adrenocortical
insufficiency, congenital adrenal hyperplasia, hypercalcemia
associated with cancer, nonsuppurative thyroiditis, rheumatoid
arthritis, epicondylitis, pemphigus
-
Stevens-Johnson
syndrome, severe psoriasis, sever seborrheic dermatitis, ankylosing
spondylitis, dermatitis herpetiformis, mycosis fungoides, exfoliative
dermatitis
-
Ulcerative
colitis, regional enteritis, severe and incapacitating allergic states
-
Acute
exacerbations of multiple sclerosis, idiopathic thrombocytopenia
purpura (IV only, IM contraindicated), optic neuritis, allergic
conjunctivitis, keratitis
Contraindications:
Precautions:
-
No
information on use in pregnancy. Use only if benefit
outweighs potential risk.
-
May
cause corneal perforation in patients with herpes simples
-
Prolonged
use may cause cataracts
-
Drug
induced adrenocortical insufficiency may be minimized by gradual dose
reduction
-
May
mask signs of infection and new infections may appear
Adverse
Reactions (Side Effects):
-
psychic
derangements, sodium/fluid retention, CHF, muscle weakness, arthralgia
-
Kaposi’s
sarcoma, tendon rupture, pathologic fracture of long bones, facial
erythema
-
aseptic
necrosis of femoral/humeral heads, Cushingoid state, convulsions,
vertigo, glaucoma, exophthalmos, increased intraocular pressure,
subcapsular cataracts
-
hyper/hypopigmentation,
urticaria, sterile abscess, cardiac arrythmias, menstrual
irregularities, decreased carbohydrate tolerance
-
Osteoporosis,
vertebral compression fractures
|
Dosage:
Administered
intravenously, intramuscularly
-
High dose therapy: IV 30 mg/kg over at least 30 minutes; may be repeated every 4-6 hours
for 48 hours (rarely, 48-72 hours)
-
In
general: Dose 10-40mg depending upon clinical problem being
treated. The larger doses
may be required for short-term management of severe, acute conditions. The initial dose usually should be given IV over several
minutes. Subsequent doses
may be given IV or IM at intervals dictated by the patient’s
response and clinical condition.
-
Infants
and children: Generally reduce the dose, but treatment should be
governed more by the severity of the condition and response of the
patient than by age or size. It
should not be less than 0.5
mg/kg every 24 hours
Dosage
must be decreased or discontinued gradually when the drug has been
administered for more than a few days. If a period of spontaneous remission occurs in a chronic condition,
treatment should be discontinues. Routine
blood studies and chest X-rays should be made at regular intervals during
prolonged therapy.
|
Home
· Military Medicine
· Sick Call · Basic Exams
· Medical Procedures
· Lab and X-ray · The Pharmacy
· The Library · Equipment
· Patient Transport
· Medical Force
Protection · Operational Safety · Operational
Settings · Special
Operations · Humanitarian
Missions · Instructions/Orders · Other Agencies · Video Gallery
· Forms · Web Links · Acknowledgements
· Help · Feedback Approved for public release;
Distribution is unlimited. The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.
Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.
Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations
Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
*This web version is provided by The Brookside Associates, LLC. It contains
original contents from the official US Navy NAVMED P-5139, but has been
reformatted for web access and includes advertising and links that were not
present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the
Department of the Navy or the Department of Defense. The presence of any
advertising on these pages does not constitute an endorsement of that product or
service by either the US Department of Defense or the Brookside Associates. The
Brookside Associates is a private organization, not affiliated with the United
States Department of Defense.
© 2015, Brookside Associates, LLC. All rights reserved
Other Brookside Products
|
|